Heartsciences INC

Fortitude Mining Holdings announces Jaime Leverton as new CEO, effective September 21, 2026, as the Zcash-focused mining company advances its proposed merger with HeartSciences Inc. and aims for a Nasdaq listing.

HeartSciences Inc. reported fiscal first quarter 2027 results, highlighting progress on its proposed merger with Fortitude Mining Holdings, Inc. and a strategic shift towards its MyoVista Insights platform.

Fortitude Mining Holdings announced robust Q2 2026 financial and operational results, including $20.9 million in revenue and $8.5 million in Adjusted EBITDA, alongside a strategic investment in HeartSciences Inc.

HeartSciences Inc. has filed an amended 8-K to include the unaudited interim financial statements of Fortitude Mining Holdings, Inc. for the six months ended June 30, 2026 and 2025, as part of their proposed merger.

HeartSciences Inc. announced Fortitude Mining Holdings, Inc. has invested approximately $1 million in the company's common stock at a 22% premium, bolstering working capital ahead of a proposed business combination.

HeartSciences Inc. has completed a private placement of approximately $1 million in common stock to Fortitude Mining Holdings, Inc., to fund operating expenses ahead of a proposed business combination.

HeartSciences Inc. reports continued operating losses and a going concern warning in its latest 10-Q filing, even as it advances its MyoVista Insights platform and pursues a merger with Fortitude Mining Holdings.

HeartSciences Inc. reports progress on its AI-ECG platforms, secures significant financing, and addresses going concern issues in its Q3 2026 filing.

HeartSciences Inc. reported minimal revenue growth and continued net losses in its Q2 2026 filing, while advancing its AI-ECG technology and securing significant capital through equity offerings.

HeartSciences Inc. reports increased cash and equity from recent capital raises, advancing its AI-ECG technology and FDA submissions despite ongoing net losses and going concern doubts.

HeartSciences Inc. reports its Q3 2025 results, highlighting ongoing efforts to obtain FDA clearance for its MyoVista wav ECG device and addressing concerns about its ability to continue as a going concern.

HeartSciences Inc. released its second quarter 2025 results, highlighting ongoing efforts towards FDA submission for its MyoVista wav ECG device and the development of AI-ECG algorithms.

HeartSciences Inc. filed its annual report for fiscal year 2026, detailing its ongoing development of AI-ECG technology and a proposed merger with Fortitude.

HeartSciences Inc. reported a significant increase in net losses for fiscal year 2025, raising substantial doubt about its ability to continue as a going concern, while actively pursuing FDA clearances for its AI-ECG devices and addressing Nasdaq listing requirements.

Heart Test Laboratories' 10-K filing details its financial status, ongoing development of AI-ECG technology, and plans for FDA submissions.

HeartSciences Inc. reports the grant of 25,000 restricted stock units to Chief Financial Officer Danielle Watson, contingent on a merger closing and continued employment.

Andrew Simpson, Director and CEO of HeartSciences Inc., received a grant of 425,000 shares of common stock as a retention bonus tied to a merger agreement.

HeartSciences Inc. director David R. Wells was granted 15,000 Restricted Stock Units, subject to shareholder approval and performance-based vesting conditions.

HeartSciences Inc. Director Bruce Bent received a grant of 15,000 Restricted Stock Units, subject to vesting conditions including shareholder approval, time-based milestones, and performance targets.

HeartSciences Inc. Chief Operating Officer Mark T. Hilz was granted 45,000 Restricted Stock Units, vesting over three years with performance and change of control accelerators.

HeartSciences Inc. Director Brian Szymczak was granted 15,000 Restricted Stock Units, subject to specific vesting conditions including shareholder approval and performance targets.

HeartSciences Inc. announces its 2026 Annual Meeting of Shareholders to address director election, an expanded equity incentive plan, officer liability exculpation, and auditor ratification.

Heart Test Laboratories has filed a definitive proxy statement with the SEC.

Heart Test Laboratories, Inc. announces its Annual Meeting of Shareholders to be held virtually on November 7, 2024, seeking shareholder approval on key proposals including the ratification of its independent accounting firm.

Heart Test Laboratories aims to raise capital through a new stock and warrant offering to fund FDA clearance efforts and commercial development of its AI-ECG technology.

Heart Test Laboratories is registering the resale of up to 34,684,859 shares of its common stock by selling stockholders, including shares issued to Mount Sinai, Lincoln Park Capital, John Q. Adams, and Matthews Southwest Holdings.

Digital Currency Group and Fortitude Mining Holdings have jointly filed a Schedule 13D, detailing their acquisition of a 9.4% stake in HeartSciences Inc. as part of a merger agreement.

Investor Ephraim Fields has filed a Schedule 13G reporting an 8.1% beneficial ownership stake in HeartSciences Inc.